Home - Products - Others - Other Targets - Citenamide

Citenamide

CAS No. 10423-37-7

Citenamide( —— )

Catalog No. M33319 CAS No. 10423-37-7

Citenamide (AY-15613) has anticancer and anticonvulsant activity and is used in the study of neurological disorders because of its sleep-promoting properties.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	219	In Stock
10MG	370	In Stock
25MG	718	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Citenamide
Note

Research use only, not for human use.
Brief Description

Citenamide (AY-15613) has anticancer and anticonvulsant activity and is used in the study of neurological disorders because of its sleep-promoting properties.
Description

Citenamide is an anticonvulsant.
In Vitro

——
In Vivo

Citenamide (Cytenamide, CYT) is an analogue of Carbamazepine (CBZ), a dibenzazepine drug used to control seizures.
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

10423-37-7
Formula Weight

235.28
Molecular Formula

C16H13NO
Purity

>98% (HPLC)
Solubility

——
SMILES

O=C(N)C1C=2C=CC=CC2C=CC=3C=CC=CC31
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Johnston A, et al. Cytenamide-formic acid (1/1). Acta Crystallogr Sect E Struct Rep Online. 2008 Jul 5;64(Pt 8):o1379-80.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

2-Epicucurbitacin B

2-epi-Cucurbitacin B is a natural product that can be obtained from Ecballium elaterium L. XVI..
Orientalide

Orientalide is a natural product for research related to life sciences.
Examorelin

Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?

Sign In Join Free